| Market Cap | ₹5,555Cr |
| ROE | 5.17% |
| P/E Ratio(TTM) | 102.62 |
| EPS(TTM) | 2.14 |
| P/B Ratio | 6.86 |
| Dividend Yield | 0.00% |
| Industry P/E | 32.98 |
| Book Value | 32.00 |
| Debt to Equity | 0.61 |
| Face Value | 2 |
| Parent Organisation | Sequent Scientific |
| Managing Director | Mr. Rajaram Narayanan |
| NSE Symbol | SEQUENT |
| FUND NAME | AUM(%) |
|---|---|
| UTI Healthcare Fund Direct Growth | 1.66% |
| Quant Small Cap Fund Direct Plan Growth | 1.58% |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 38.88 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 32.32 | ||
| Cohance Lifesciences | NA (0.00%) | 69.40 | ||
| Wockhardt | NA (0.00%) | -407.25 |